IBDEI0RV ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13069,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13069,1,3,0)
 ;;=3^Hypothyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,13069,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,13069,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,13070,0)
 ;;=E06.0^^53^585^53
 ;;^UTILITY(U,$J,358.3,13070,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13070,1,3,0)
 ;;=3^Thyroiditis,Acute
 ;;^UTILITY(U,$J,358.3,13070,1,4,0)
 ;;=4^E06.0
 ;;^UTILITY(U,$J,358.3,13070,2)
 ;;=^2692
 ;;^UTILITY(U,$J,358.3,13071,0)
 ;;=E06.1^^53^585^54
 ;;^UTILITY(U,$J,358.3,13071,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13071,1,3,0)
 ;;=3^Thyroiditis,Subacute
 ;;^UTILITY(U,$J,358.3,13071,1,4,0)
 ;;=4^E06.1
 ;;^UTILITY(U,$J,358.3,13071,2)
 ;;=^119376
 ;;^UTILITY(U,$J,358.3,13072,0)
 ;;=C73.^^53^585^37
 ;;^UTILITY(U,$J,358.3,13072,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13072,1,3,0)
 ;;=3^Malig Neop of Thyroid Gland
 ;;^UTILITY(U,$J,358.3,13072,1,4,0)
 ;;=4^C73.
 ;;^UTILITY(U,$J,358.3,13072,2)
 ;;=^267296
 ;;^UTILITY(U,$J,358.3,13073,0)
 ;;=E10.21^^53^585^8
 ;;^UTILITY(U,$J,358.3,13073,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13073,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,13073,1,4,0)
 ;;=4^E10.21
 ;;^UTILITY(U,$J,358.3,13073,2)
 ;;=^5002589
 ;;^UTILITY(U,$J,358.3,13074,0)
 ;;=E10.9^^53^585^12
 ;;^UTILITY(U,$J,358.3,13074,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13074,1,3,0)
 ;;=3^DM Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,13074,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,13074,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,13075,0)
 ;;=E11.21^^53^585^17
 ;;^UTILITY(U,$J,358.3,13075,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13075,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Nephropathy
 ;;^UTILITY(U,$J,358.3,13075,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,13075,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,13076,0)
 ;;=E11.39^^53^585^18
 ;;^UTILITY(U,$J,358.3,13076,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13076,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Ophthalmic Complication NEC
 ;;^UTILITY(U,$J,358.3,13076,1,4,0)
 ;;=4^E11.39
 ;;^UTILITY(U,$J,358.3,13076,2)
 ;;=^5002643
 ;;^UTILITY(U,$J,358.3,13077,0)
 ;;=E11.43^^53^585^15
 ;;^UTILITY(U,$J,358.3,13077,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13077,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Autonomic Neuropathy
 ;;^UTILITY(U,$J,358.3,13077,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,13077,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,13078,0)
 ;;=E11.59^^53^585^13
 ;;^UTILITY(U,$J,358.3,13078,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13078,1,3,0)
 ;;=3^DM Type 2 w/ Circulatory Complications NEC
 ;;^UTILITY(U,$J,358.3,13078,1,4,0)
 ;;=4^E11.59
 ;;^UTILITY(U,$J,358.3,13078,2)
 ;;=^5002652
 ;;^UTILITY(U,$J,358.3,13079,0)
 ;;=E11.618^^53^585^14
 ;;^UTILITY(U,$J,358.3,13079,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13079,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Arthropathy NEC
 ;;^UTILITY(U,$J,358.3,13079,1,4,0)
 ;;=4^E11.618
 ;;^UTILITY(U,$J,358.3,13079,2)
 ;;=^5002654
 ;;^UTILITY(U,$J,358.3,13080,0)
 ;;=E11.621^^53^585^16
 ;;^UTILITY(U,$J,358.3,13080,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13080,1,3,0)
 ;;=3^DM Type 2 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,13080,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,13080,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,13081,0)
 ;;=E11.622^^53^585^20
 ;;^UTILITY(U,$J,358.3,13081,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,13081,1,3,0)
 ;;=3^DM Type 2 w/ Skin Ulcer NEC
 ;;^UTILITY(U,$J,358.3,13081,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,13081,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,13082,0)
 ;;=E11.65^^53^585^19
 ;;^UTILITY(U,$J,358.3,13082,1,0)
 ;;=^358.31IA^4^2
